摘要 |
The use of ribavirin and/or pegylated interferon alfa for the preparation of a pharmaceutical composition for the treatment of chronic hepatitis C infectio n comprising a therapeutically weight-effective amount of ribavirin and a therapeutically effective amount of pegylated, e.g, pegylated interferon-alf a- 2b or -2a, is disclosed.
|